parsaclisib,obinutuzumab,bendamustine
roche,incyte,teva pharmaceuticals
['obinu', 'follicular', 'lymsm', 'lymphoma', 'parsaclisib', 'bendamustine']
#eha2022 a phase 1 study evaluating safety and efficacy of #parsaclisib in combination with obinutuzumab plus bendamustine in pts with r/r follicular #lymphoma #lymsm 
Lymphoma Unit @Hospital_FJD & @UICOquironsalud. Board member @sehh_es & @SIOGorg. Councilor @EHA_Hematology Executive Board. Chairman SWG “Aging and Hematology”